Chief Executive Officer Greenleaf Peter sale 126,981 shares of Aurinia Pharmaceuticals Inc [AUPH]

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Aurinia Pharmaceuticals Inc shares valued at $711,094 were sold by Greenleaf Peter on Mar 06 ’24. At $5.60 per share, Greenleaf Peter sold 126,981 shares. The insider’s holdings dropped to 1,522,114 shares worth approximately $7.99 million following the completion of this transaction.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Also, Robertson Stephen P. sold 57,745 shares, netting a total of over 323,372 in proceeds. Following the sale of shares at $5.60 each, the insider now holds 443,824 shares.

Before that, Donley Matthew Maxwell had sold 40,665 shares from its account. In a trade valued at $224,064, the EVP, Ops & Strategy traded Aurinia Pharmaceuticals Inc shares for $5.51 each. Upon closing the transaction, the insider’s holdings decreased to 40,665 shares, worth approximately $3.07 million.

As published in a research note from Oppenheimer on November 04, 2022, Aurinia Pharmaceuticals Inc [AUPH] has been rated down from an Outperform to a Perform. As of December 10, 2021, Oppenheimer has increased its “Perform” rating to a “an Outperform” for AUPH. Earlier on October 28, 2021, Oppenheimer downgraded its rating. Their new recommendation was “a Perform” for AUPH stock which previously was a “an Outperform”.

Analyzing AUPH Stock Performance

During the last five days, there has been a drop of approximately -4.89%. Over the course of the year, Aurinia Pharmaceuticals Inc shares have dropped approximately -41.60%. Shares of the company reached a 52-week high of $9.43 on 01/10/24 and a 52-week low of $5.16 on 03/13/24. A 50-day SMA is recorded $7.16, while a 200-day SMA reached $8.62. Nevertheless, trading volume fell to 1.34 million shares from 1.47 million shares the previous day.

Support And Resistance Levels for Aurinia Pharmaceuticals Inc (AUPH)

According to the 24-hour chart, there is a support level at 5.18, which, if violated, would cause prices to drop to 5.10. In the upper region, resistance lies at 5.31. The next price resistance is at 5.36. RSI (Relative Strength Index) is 26.97 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.36, which suggests the price will decrease in the coming days. Percent R is at 90.72%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Aurinia Pharmaceuticals Inc subject to short interest?

Stocks of Aurinia Pharmaceuticals Inc saw a sharp steep in short interest on Feb 29, 2024 dropping by -6.43 million shares to 12.1 million. Data from Yahoo Finance shows that the short interest on Jan 31, 2024 was 18.53 million shares. A decline of -53.14% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.79 of the overall float, the days-to-cover ratio (short ratio) decline to 3.79.

Which companies own the most shares of Aurinia Pharmaceuticals Inc (AUPH)?

On January 25, 2021, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $35.

Most Popular